$2.45
1.24% today
Nasdaq, Nov 26, 05:17 pm CET
ISIN
US31189P1021
Symbol
FATE
Sector
Industry

Fate Therapeutics, Inc. Target price 2024 - Analyst rating & recommendation

Fate Therapeutics, Inc. Classifications & Recommendation:

Buy
24%
Hold
76%

Fate Therapeutics, Inc. Price Target

Target Price $6.33
Price $2.42
Potential
Number of Estimates 12
12 Analysts have issued a price target Fate Therapeutics, Inc. 2025 . The average Fate Therapeutics, Inc. target price is $6.33. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 17 analysts: 4 Analysts recommend Fate Therapeutics, Inc. to buy, 13 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Fate Therapeutics, Inc. stock has an average upside potential 2025 of . Most analysts recommend the Fate Therapeutics, Inc. stock at Hold.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 63.53 13.04
34.03% 79.48%
EBITDA Margin -250.79% -1,431.78%
18.03% 470.90%
Net Margin -293.98% -1,425.27%
14.57% 384.82%

17 Analysts have issued a sales forecast Fate Therapeutics, Inc. 2024 . The average Fate Therapeutics, Inc. sales estimate is

$13.0m
Unlock
. This is
3.05% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$20.0m 48.70%
Unlock
, the lowest is
$10.3m 23.44%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $63.5m 34.03%
2024
$13.0m 79.48%
Unlock
2025
$3.7m 71.67%
Unlock
2026
$4.1m 10.99%
Unlock
2027
$16.8m 308.78%
Unlock
2028
$59.8m 256.68%
Unlock

5 Analysts have issued an Fate Therapeutics, Inc. EBITDA forecast 2024. The average Fate Therapeutics, Inc. EBITDA estimate is

$-187m
Unlock
. This is
5.14% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-181m 1.84%
Unlock
, the lowest is
$-192m 7.95%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-159m 45.92%
2024
$-187m 17.17%
Unlock
2025
$-204m 9.48%
Unlock
2026
$-210m 2.87%
Unlock

EBITDA Margin

2023 -250.79% 18.03%
2024
-1,431.78% 470.90%
Unlock
2025
-5,533.33% 286.47%
Unlock
2026
-5,128.07% 7.32%
Unlock

18 Fate Therapeutics, Inc. Analysts have issued a net profit forecast 2024. The average Fate Therapeutics, Inc. net profit estimate is

$-186m
Unlock
. This is
1.10% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-134m 28.48%
Unlock
, the lowest is
$-216m 15.15%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-187m 43.64%
2024
$-186m 0.49%
Unlock
2025
$-191m 2.53%
Unlock
2026
$-168m 11.61%
Unlock
2027
$-144m 14.38%
Unlock
2028
$-136m 5.63%
Unlock

Net Margin

2023 -293.98% 14.57%
2024
-1,425.27% 384.82%
Unlock
2025
-5,158.20% 261.91%
Unlock
2026
-4,107.52% 20.37%
Unlock
2027
-860.31% 79.06%
Unlock
2028
-227.62% 73.54%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -1.64 -1.63
43.64% 0.61%
P/E negative
EV/Sales 5.96

18 Analysts have issued a Fate Therapeutics, Inc. forecast for earnings per share. The average Fate Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-1.63
Unlock
. This is
1.21% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-1.18 28.48%
Unlock
, the lowest is
$-1.90 15.15%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-1.64 43.64%
2024
$-1.63 0.61%
Unlock
2025
$-1.67 2.45%
Unlock
2026
$-1.48 11.38%
Unlock
2027
$-1.27 14.19%
Unlock
2028
$-1.19 6.30%
Unlock

P/E ratio

Current -1.46 8.96%
2024
-1.48 1.37%
Unlock
2025
-1.45 2.03%
Unlock
2026
-1.64 13.10%
Unlock
2027
-1.91 16.46%
Unlock
2028
-2.03 6.28%
Unlock

Based on analysts' sales estimates for 2024, the Fate Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
21.14
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 5.78 5,354.55%
2024
5.96 3.07%
Unlock
2025
21.03 253.00%
Unlock
2026
18.95 9.91%
Unlock
2027
4.63 75.54%
Unlock
2028
1.30 71.96%
Unlock

P/S ratio

Current 20.49 835.33%
2024
21.14 3.15%
Unlock
2025
74.62 253.00%
Unlock
2026
67.22 9.91%
Unlock
2027
16.45 75.54%
Unlock
2028
4.61 71.96%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today